博雅生物(300294.SZ)股東懿康投資擬清倉減持不超3.4477%股份
格隆匯4月8日丨博雅生物(300294.SZ)公佈,近日,公司接到公司股東上海高特佳懿康投資合夥企業(有限合夥)(“懿康投資”)出具的《關於減持博雅生物股份計劃的告知函》,懿康投資擬自公告披露之日起十五個交易日後的六個月內,通過集中競價、大宗交易等合法合規的方式減持博雅生物股份不超過1468.5192萬股(佔公司總股份的3.4477%,總股份以扣減公司回購專户的數量為基準)。
截至目前,懿康投資持有公司股份1468.5192萬股,佔公司總股份的3.4477%。懿康投資的管理人為公司控股股東深圳市高特佳投資集團有限公司(“高特佳集團”)之控股子公司深圳市高特佳弘瑞投資有限公司,故懿康投資為高特佳集團一致行動人。
截至目前,高特佳集團及其一致行動人合計持有公司股份約1.5億股,佔公司總股本的35.1305%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.